tradingkey.logo

enVVeno Medical Corp

NVNO
0.355USD
+0.013+3.74%
收盤 12/24, 13:00美東報價延遲15分鐘
7.17M總市值
虧損本益比TTM

enVVeno Medical Corp

0.355
+0.013+3.74%

關於 enVVeno Medical Corp 公司

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.

enVVeno Medical Corp簡介

公司代碼NVNO
公司名稱enVVeno Medical Corp
上市日期May 31, 2018
CEOBerman (Robert A)
員工數量37
證券類型Ordinary Share
年結日May 31
公司地址70 Doppler
城市IRVINE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編92618
電話19492612900
網址https://envveno.com/
公司代碼NVNO
上市日期May 31, 2018
CEOBerman (Robert A)

enVVeno Medical Corp公司高管

名稱
名稱/職務
職務
持股
持股變動
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
97.44K
--
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
11.15K
+7.73%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
9.29K
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
1.60K
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Jennifer Bright
Ms. Jennifer Bright
Chief Financial Officer
Chief Financial Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
97.44K
--
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
11.15K
+7.73%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
9.29K
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
1.60K
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 12月4日 週四
更新時間: 12月4日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Satterfield (Thomas A Jr)
9.02%
Perceptive Advisors LLC
8.70%
Kingdon Capital Management, L.L.C.
6.72%
The Vanguard Group, Inc.
4.26%
CM Management, LLC
2.97%
其他
68.33%
持股股東
持股股東
佔比
Satterfield (Thomas A Jr)
9.02%
Perceptive Advisors LLC
8.70%
Kingdon Capital Management, L.L.C.
6.72%
The Vanguard Group, Inc.
4.26%
CM Management, LLC
2.97%
其他
68.33%
股東類型
持股股東
佔比
Individual Investor
10.76%
Investment Advisor
10.13%
Private Equity
8.70%
Hedge Fund
7.28%
Investment Advisor/Hedge Fund
1.91%
Research Firm
1.34%
Venture Capital
0.21%
其他
59.67%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
76
5.69M
28.14%
-667.58K
2025Q2
75
3.80M
19.76%
-3.06M
2025Q1
73
3.82M
21.80%
-3.21M
2024Q4
75
4.44M
25.31%
-1.95M
2024Q3
71
5.27M
30.14%
+688.15K
2024Q2
65
3.79M
29.68%
-1.51M
2024Q1
67
4.10M
32.04%
-789.97K
2023Q4
59
4.71M
36.59%
+2.14M
2023Q3
57
2.68M
28.24%
-1.00M
2023Q2
55
2.71M
28.61%
-1.36M
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Perceptive Advisors LLC
1.28M
6.68%
+1.28M
--
Jun 30, 2025
Kingdon Capital Management, L.L.C.
1.36M
7.06%
+500.00K
+58.19%
Sep 02, 2025
The Vanguard Group, Inc.
698.34K
3.63%
+97.43K
+16.21%
Jun 30, 2025
Westside Investment Management, LLC
279.52K
1.45%
+20.48K
+7.90%
Jun 30, 2025
Geode Capital Management, L.L.C.
199.51K
1.04%
+2.21K
+1.12%
Jun 30, 2025
J.P. Morgan Securities LLC
182.30K
0.95%
-11.91K
-6.13%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
佔比0%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
公告日期
類型
比率
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1

常見問題

enVVeno Medical Corp的前五大股東是誰?

enVVeno Medical Corp的前五大股東如下:
Perceptive Advisors LLC
持有股份:1.28M
佔總股份比例:6.68%。
Kingdon Capital Management, L.L.C.
持有股份:1.36M
佔總股份比例:7.06%。
The Vanguard Group, Inc.
持有股份:698.34K
佔總股份比例:3.63%。
Westside Investment Management, LLC
持有股份:279.52K
佔總股份比例:1.45%。
Geode Capital Management, L.L.C.
持有股份:199.51K
佔總股份比例:1.04%。

enVVeno Medical Corp的前三大股東類型是什麼?

enVVeno Medical Corp 的前三大股東類型分別是:
Satterfield (Thomas A Jr)
Perceptive Advisors LLC
Kingdon Capital Management, L.L.C.

有多少機構持有enVVeno Medical Corp(NVNO)的股份?

截至2025Q3,共有76家機構持有enVVeno Medical Corp的股份,合計持有的股份價值約為5.69M,占公司總股份的28.14% 。與2025Q2相比,機構持股有所增加,增幅為8.37%。

哪個業務部門對enVVeno Medical Corp的收入貢獻最大?

在--,--業務部門對enVVeno Medical Corp的收入貢獻最大,創收--,占總收入的--% 。
KeyAI